{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:12:11Z","timestamp":1790435531529,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,7,16]],"date-time":"2017-07-16T00:00:00Z","timestamp":1500163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Decision\u2010making is a complex process. The aim of our study was to assess factors associated with the choice of the first biological treatment in patients with moderate\u2010to\u2010severe psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data on all patients included in the French prospective, observational, cohort, Psobioteq and initiating a first biologic prescription between July 2012 and July 2016 were analysed. Demographic information and clinical features were collected during routine clinical assessments by the dermatology team at the recruiting centres using a standardized case report form. The primary outcome was the nature of the first biologic treatment. Four groups were identified as follows: adalimumab, etanercept, ustekinumab and infliximab groups. Factors associated with the choice of the first biological agent were determined by a multinomial logistic regression model adjusted on year of inclusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study population included the 830 biological\u2010na\u00efve patients who initiated a first biological agent. The mean age was 46.6\u00a0years (\u00b1<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content> 13.9), and 318 patients (38.3%) were female. The most commonly prescribed biologic was adalimumab: 355 (42.8%) patients, then etanercept (<jats:italic>n<\/jats:italic>\u00a0=\u00a0247, 29.8%), ustekinumab (<jats:italic>n<\/jats:italic>\u00a0=\u00a0194, 23.4%) and infliximab (<jats:italic>n<\/jats:italic>\u00a0=\u00a034, 4.0%). In the multinomial logistic regression analysis, patients were significantly more likely to receive adalimumab if they had a severe psoriasis as defined by baseline <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> or if they had psoriatic arthritis compared to etanercept (<jats:styled-content style=\"fixed-case\">aOR<\/jats:styled-content>, 0.42; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 0.16\u20131.07) and ustekinumab (<jats:styled-content style=\"fixed-case\">aOR<\/jats:styled-content>, 0.15; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 0.04\u20130.52). Patients were significantly more likely to receive ustekinumab (<jats:styled-content style=\"fixed-case\">aOR<\/jats:styled-content>, 2.39; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 1.04\u20135.50) if they had a positive screening for latent tuberculosis compared to adalimumab. Younger patients were also more likely to receive ustekinumab. Patients with chronic obstructive pulmonary disease were more likely to be prescribed ustekinumab or etanercept compared to adalimumab. There was a trend in favour of etanercept prescription in patients with cardiovascular comorbidities, metabolic syndrome and in patients with a history of cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We identified patient\u2010 and disease\u2010related factors that have important influence on the choice of the first biological agent in clinical practice. Clinicians appear to have a holistic approach to patient characteristics when choosing a biological agent in psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14406","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T20:56:41Z","timestamp":1497387401000},"page":"2046-2054","source":"Crossref","is-referenced-by-count":31,"title":["Factors associated with the choice of the first biologic in psoriasis: real\u2010life analysis from the Psobioteq cohort"],"prefix":"10.1111","volume":"31","author":[{"given":"E.","family":"Sbidian","sequence":"first","affiliation":[{"name":"D\u00e9partement de Dermatologie AP\u2010HP H\u00f4pitaux Universitaires Henri Mondor UPEC Cr\u00e9teil France"},{"name":"INSERM Centre d'Investigation Clinique 1430 Cr\u00e9teil France"},{"name":"EA 7379 EpidermE Universit\u00e9 Paris\u2010Est Cr\u00e9teil (UPEC) Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Giboin","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biostatistique, Sant\u00e9 Publique et Information M\u00e9dicale Centre de Pharmaco\u2010\u00e9pid\u00e9miologie CIC 1421 AP\u2010HP H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re \u2013 Charles Foix Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bachelez","sequence":"additional","affiliation":[{"name":"Service de Dermatologie Institut Imagine AP\u2010HP H\u00f4pital Saint\u2010Louis INSERM UMR 1163 SorbonneParis Cit\u00e9 Universit\u00e9 Paris Diderot Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie H\u00f4pitaux Universitaires de Toulouse UMR INSERM 1056 Universit\u00e9 Paul Sabatier Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beylot\u2010Barry","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie INSERM U1053 H\u00f4pital Saint\u2010Andr\u00e9 Universit\u00e9 de Bordeaux Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dupuy","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie INSERM CIC 1414 Centre Hospitalier Universitaire de Rennes H\u00f4pital Pontchaillou Universit\u00e9 de Rennes 1 Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Viguier","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie H\u00f4pitaux Universitaires Robert Debr\u00e9 Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010P.","family":"Lacour","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie Centre de R\u00e9f\u00e9rence Maladies Rares H\u00f4pital l'Archet 2 Centre Hospitalier Universitaire de Nice Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010L.","family":"Schmutz","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie et Allergologie H\u00f4pitaux de Brabois Centre Hospitalier R\u00e9gional Universitaire de Nancy Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bravard","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie Groupe Hospitalier du Havre Le Havre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mah\u00e9","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie H\u00f4pital Victor Dupouy Argenteuil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Beneton","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie Centre Hospitalier du Mans Le Mans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Misery","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie Centre Hospitalier R\u00e9gional Universitaire de Brest Brest France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Delaporte","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie Centre Hospitalier R\u00e9gional Universitaire de Lille Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Modiano","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie Groupement des H\u00f4pitaux de l'Institut Catholique de Lille H\u00f4pital Saint\u2010Vincent\u2010de\u2010Paul Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Barbarot","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie Centre Hospitalier Universitaire de Nantes Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Regnier","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie AP\u2010HP H\u00f4pitaux Universitaires Cochin Universit\u00e9 Paris Descartes Paris V Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Jullien","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie HCL Centre Hospitalier Universitaire H\u00f4pital Edouard Herriot Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u2010A.","family":"Richard","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie Centre Hospitalier Universitaire H\u00f4pital La Timone Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Joly","sequence":"additional","affiliation":[{"name":"Department of Dermatology Rouen University Hospital INSERM U 1234 Normandie University Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tubach","sequence":"additional","affiliation":[{"name":"D\u00e9partement Biostatistique, Sant\u00e9 Publique et Information M\u00e9dicale Centre de Pharmaco\u2010\u00e9pid\u00e9miologie CIC 1421 AP\u2010HP H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re \u2013 Charles Foix Paris France"},{"name":"Universit\u00e9 Pierre et Marie Curie Sorbonne Universit\u00e9s Paris France"},{"name":"UMR 1123 CIC 1421 ECEVE INSERM Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Chosidow","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie AP\u2010HP H\u00f4pitaux Universitaires Henri Mondor UPEC Cr\u00e9teil France"},{"name":"INSERM Centre d'Investigation Clinique 1430 Cr\u00e9teil France"},{"name":"EA 7379 EpidermE Universit\u00e9 Paris\u2010Est Cr\u00e9teil (UPEC) Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13354"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.391"},{"key":"e_1_2_6_5_1","unstructured":"NICE guidelines. Available from:www.nice.org.uk. Accessed on October 2012."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12045"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.78"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11162.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11142.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13633"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw129"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13908"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10213.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.10.001"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14406","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/chorus\/v1\/articles\/10.1111%2Fjdv.14406","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:14:52Z","timestamp":1695561292000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,16]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/jdv.14406"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14406","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,16]]}}}